Pharmacokinetics and safety of a phenytoin prodrug given IV or IM in patients

I. E. Leppik; B. A. Boucher; B. J. Wilder; V. S. Murthy; C. Watridge; N. M. Graves; R. J. Rangel; C. A. Rask; P. Turlapaty

doi:10.1212/WNL.40.3_Part_1.456

Full PDF

Citation

Permissions

Make Comment

See Comments

Downloads

Abstract

ACC-9653, a prodrug of phenytoin synthesized to be water soluble, is converted to phenytoin by phos-phatases. In this study, 43 patients received ACC-9653 IV or IM. Side effects were transient and minor. The conversion half-lives of ACC-9653 after intravenous and intramuscular administration averaged 8.4 and 32.7 minutes, respectively. Peak phenytoin concentrations occurred 42 minutes after IV and 151 minutes after IM administration.

AAN Members

We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.

Google Safari Microsoft Edge Firefox

Click here to login

AAN Non-Member Subscribers

Click here to login

Purchase access

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here

Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.

Letters: Rapid online correspondence

No comments have been published for this article.

Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
Submit only on articles published within 6 months of issue date.
Do not be redundant. Read any comments already posted on the article prior to submission.
Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

Title *

Author Information

NOTE: The first author must also be the corresponding author of the comment.

Authors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Publishing Agreement

I, the first and corresponding author, verify that I have read the contents of the PUBLISHING AGREEMENT form. *

I, the first and corresponding author, verify my disclosures and those of my co-authors are up to date at http://submit.neurology.org. *

Select only one of the three options below: *

I am an Author of this Work, and the Work was prepared on my own time - not as part of my duties as an employee.

I prepared (or cooperated in the preparation of) the Work as part of my duties as an employee, and the Work is, therefore, a "work made for hire", as defined by the United States Copyright Act of 1976, as amended.

I prepared (or participated in the preparation of) the Work as part of my official duties as an officer or employee of the United States Government.

NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Alert Me

Alert me when eletters are published

Main menu

User menu

Search

Pharmacokinetics and safety of a phenytoin prodrug given IV or IM in patients

Citation Manager Formats

Abstract

AAN Non-Member Subscribers

Purchase access

Letters: Rapid online correspondence

Plain text

Vertical Tabs

You May Also be Interested in

► Watch

Alert Me

Articles

About

Submit

Subscribers

Main menu

User menu

Search

Share

Pharmacokinetics and safety of a phenytoin prodrug given IV or IM in patients

Citation Manager Formats

Share

Abstract

AAN Members

AAN Non-Member Subscribers

Purchase access

Letters: Rapid online correspondence

Plain text

Vertical Tabs

You May Also be Interested in

► Watch

Related Articles

Alert Me

Articles

About

Submit

Subscribers